• Company
• 3 Korean companies accelerate Stelara biosimilar development
• by Ji Yong Jun Jan 19, 2022 06:06am

• Policy
• Bill for Rotarix·RotaTeq to be covered by NIP
• by Lee, Jeong-Hwan Jan 19, 2022 06:06am

• Company
• Exporting medicines to North America ↑ 2.6 times in 2 years
• by Kim, Jin-Gu Jan 19, 2022 06:06am

• Policy
• The benefit standard for Braftovi & Lorviqua was set
• by Lee, Hye-Kyung Jan 19, 2022 06:06am

• Policy
• Daewoong tx are being developed for skin side effects
• by Lee, Tak-Sun Jan 18, 2022 06:06am

• Policy
• Discord in system hinder coverage of rare disease drugs
• by Lee, Jeong-Hwan Jan 18, 2022 06:06am

• Policy
• The gov will push for a refund on losses from suspension
• by Kim, Jung-Ju Jan 18, 2022 06:05am

• Company
• Pharma exports exceed ₩9 trillion in 2021
• by Kim, Jin-Gu Jan 18, 2022 06:05am

• Opinion
• [Desk] The task of reimbursement for ultra-high-priced drugs
• by Kim, Jung-Ju Jan 18, 2022 06:05am

• Company
• First PIK3CA-targeting ‘Piqray’ lands in general hospitals
• by Eo, Yun-Ho Jan 17, 2022 05:51am